Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165872 | 0.95 | CTSS (0.60) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3165929 | 0.95 | CTSS (0.58) | CTSSCTSKCTSLCTSBCXCR3 | |
| Trifluoroacetic Acid SCHEMBL3159693 | 0.95 | CTSS (0.62) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3169427 | 0.94 | CTSS (0.58) | CTSSCTSKCTSLCTSBCXCR3 | |
| Trifluoroacetic Acid SCHEMBL3166721 | 0.93 | CTSS (0.48) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3166832 | 0.92 | CTSL (0.49) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3174935 | 0.92 | CTSS (0.55) | CTSSCTSKCTSLCTSBCXCR3 | |
| Trifluoroacetic Acid SCHEMBL3165907 | 0.92 | CTSS (0.55) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3166874 | 0.91 | CTSL (0.49) | CTSSCTSKCTSLCTSBHIF1A | |
| Trifluoroacetic Acid SCHEMBL3166613 | 0.90 | CTSS (0.55) | CTSSCTSKCTSLCTSBCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | claimed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | claimed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | claimed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | CTSS 15/4885CTSK 65/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.